Review on application and development of pharmacogenomics of adverse drug reactions

Journal of Holistic Integrative Pharmacy, Год журнала: 2025, Номер 6(1), С. 105 - 116

Опубликована: Март 1, 2025

Язык: Английский

---

Personalized medicine: An alternative for Cancer Treatment

Cancer Treatment and Research Communications, Год журнала: 2024, Номер 42, С. 100860 - 100860

Опубликована: Янв. 1, 2024

The incidence of cancer continues to increase worldwide, resulting in significant physical, emotional, and financial challenges for individuals, families, communities, healthcare systems. Cancer is projected be responsible approximately 10 million deaths 2020, accounting one six globally. Prostate, colon, lung, breast cancers are the most common types cancer. In India, it estimated that there will around 2.7 patients by 2020. Personalized medicine has potential offer an alternative approach treatment. Precision medicine, often known as personalized a new treatment technique focuses on tailoring medication each patient's specific genetic, biochemical, lifestyle factors. goal optimize tumor response while minimizing therapy side effects, improved patient care quality life. allows creation focused medicines address gene mutations leveraging knowledge about cancer, including its genetic makeup. Ongoing research seeks detect modifications diverse types, produce novel diagnostic tools, develop treatments particularly target these changes. recent years, achieved major advances solid tumors, with promise improve precision, reduce well enhance outcomes therapy. This review aims objectively evaluate transformation treatment, emphasizing shift towards more precise methodology.

Язык: Английский

---

A preliminary exploration of liver microsomes and PBPK to uncover the impact of CYP3A4/5 and CYP2C19 on tacrolimus and voriconazole drug-drug interactions

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Фев. 21, 2025

Solid transplant recipients are at increased risk for invasive aspergillosis. Tacrolimus and Voriconazole is one of the most frequently utilized treatments those with fungal infections. However, it difficult to use them properly due interaction between them. This study aimed investigate potential drug-drug by multiple methods, including in vitro liver microsome method PBPK(Physiologically Based Pharmacokinetic) model. Midazolam testosterone were used as probe substrates evaluate individual differences CYP3A4/5 metabolic activity. A comprehensive analysis was also conducted based on STITCH database DD-Inter system. Furthermore, a PBPK model constructed data from literature simulate real process vivo. The research employed methodologies demonstrate that co-administration significantly enhances concentrations, considering genotypes activity genotypes. findings indicated decrease relative percentages midazolam metabolites increasing concentration. Moreover, results residual 30-minute incubation group revealed exerts mild inhibitory effect metabolism Tacrolimus. system suggested share strong association metabolism, likely interacting CYP2C19. result AUC increases co-therapy. intermediate CYP2C19 metabolizers (IM) highest 10.1 µmol·min/L, followed poor (PM) 8.13 extensive (EM) 2.18 µmol·min/L. And genotype CYP3A5 metabolizer had 3.13µmol·min/L 2.18µmol·min/L. Microsomal studies, models, other analyses have comprehensively elucidated impact concentrations. These can serve valuable point reference concurrently administering these two medications. indicate play an important role development DDI during concurrent treatment, which may some guidance clinical medication.

Язык: Английский

---

A Case Study on Complete Pathological Response in Advanced Rectal Cancer Patient with Oxaliplatin-based Chemotherapy without Cumulative Neurotoxicity

Journal of Gastrointestinal Cancer, Год журнала: 2025, Номер 56(1)

Опубликована: Апрель 16, 2025

Язык: Английский

---

Anti‐Obesity Medication in the Management of Children and Adolescents With Obesity: Recent Developments and Research Gaps

Clinical Endocrinology, Год журнала: 2024, Номер unknown

Опубликована: Сен. 11, 2024

ABSTRACT Background Paediatric obesity is a global public health concern. While in most countries the incidence keeps rising, need for effective and long‐term management children adolescents living with this chronic, relapsing disease pressing. Health behaviour lifestyle treatment (HBLT) recommended as first‐line treatment. Methods Narrative review. Results A new generation of recently approved anti‐obesity medications (AOM) now has potential to fill gap between limited effects on body mass index (BMI) by HBLT alone large metabolic bariatric surgery aged 12 years older. While, semaglutide phentermine/topiramate, effectiveness substantial relevant, but mostly mild moderate adverse events, there evidence regarding safety, outcomes beyond BMI reduction data certain groups patients, such < minority groups. When integrating AOM into national healthcare systems it should be offered part comprehensive patient‐centred approach. Conclusion This article summarizes recent developments, integration paediatric management, identifies research gaps.

Язык: Английский

---

CLINICAL IMPACT OF DPYD GENOTYPING AND DOSE ADJUSTMENT IN CANDIDATES FOR FLUOROPYRIMIDINE TREATMENT

Heliyon, Год журнала: 2024, Номер 10(23), С. e40808 - e40808

Опубликована: Дек. 1, 2024

Язык: Английский

---